Your browser doesn't support javascript.
loading
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
Huang, YeXing; Zhang, LiHong; He, MinKe; Lai, ZhiCheng; Bu, XiaoYun; Wen, DongSheng; Li, QiJiong; Xu, Li; Wei, Wei; Zhang, YaoJun; Zhou, ZhongGuo; Chen, MinShan; Guo, RongPing; Shi, Ming; Kan, Anna.
Afiliação
  • Huang Y; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhang L; Department of Pathology, 71067Sun Yat-sen University Cancer Center, Guangzhou, China.
  • He M; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Lai Z; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Bu X; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Wen D; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Li Q; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Xu L; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Wei W; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhang Y; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Zhou Z; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Chen M; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Guo R; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Shi M; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Kan A; Department of Hepatobiliary Oncology, 71067Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Technol Cancer Res Treat ; 21: 15330338221117389, 2022.
Article em En | MEDLINE | ID: mdl-36529949

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Technol Cancer Res Treat Assunto da revista: NEOPLASIAS / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Quimioembolização Terapêutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Technol Cancer Res Treat Assunto da revista: NEOPLASIAS / TERAPEUTICA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Estados Unidos